^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Matched therapies for advanced gastric cancer based on genotype: A real-world study in China.

Published date:
05/19/2021
Excerpt:
...11 (37%) harbored c-MET amplification/overexpression (received savolitinib or crizotinib, cohort A)....three of 11 patients had an objective response (1 complete response and 2 partial responses, objective response rate (ORR) 27%), disease control rate (DCR) was 45%, median progression-free survival (mPFS) was 2.1 months, and median overall survival (mOS) was 3.7 months.
DOI:
10.1200/JCO.2021.39.15_suppl.e16098
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer

Published date:
09/07/2021
Excerpt:
Volitinib demonstrated great antitumor activity in MET and pMET high expression MKN45 cells and xenograft.
DOI:
https://doi.org/10.3389/fonc.2021.719217